At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
LTX-315 and TILscombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase II Single Centre Study Investigating the Safety and Efficacy of LTX-315 and Adoptive T-cell Therapy in Patients With Advanced/Metastatic Soft Tissue Sarcoma (ATLAS-IT-04)
In Brief
A Phase 2 clinical trial evaluating LTX-315 and TILs for Soft Tissue Sarcoma. Completed, enrolled 6 participants across 1 site.
Detailed Summary
ATLAS-IT-04 is a two part, single arm study designed to determine the safety and effectiveness of LTX-315 to induce T-cell infiltration prior to TIL expansion in patients with soft tissue sarcoma. Following intratumoural injection of LTX-315 to a selected lesion, the lesion will be extracted for T-cell culture, expansion and infusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesDenmark
CollaboratorsHerlev Hospital
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartDec 2018
Primary CompletionJul 2021
Study CompletionOct 2021
TodayJul 2026
First PostedOct 31, 2018
Enrollment StartDec 28, 2018
Primary CompletionJul 2, 2021
Study CompletionOct 11, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.7 years ago
Interventions
LTX-315 and TILscombination
Intratumoural injection of LTX-315 and infusion of TILs